tirbanibulin-kx2-391

Description: Tirbanibulin (also known as KXO1 and KX2-391) is novel, potent and the first clinical peptidomimetic Src kinase inhibitor with potential anticancer activity. It inhibits the peptide substrate site of Src with GI50s of 9-60 nM in cell-based assays. KX2-391 is an orally bioavailable small molecule Src inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, Src kinase inhibitor KX2-391 specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.

References: Dig Dis Sci. 2009 Jul; 54(7):1465-74; Eur J Med Chem. 2011 Oct; 46(10):4853-8.

Related CAS: 1038395-65-1 (HCl); 1080645-95-9 (Tirbanibulin Mesylate); 897016-82-9 (free base)

Chemical Name: (E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanone

InChi Key: YYLKKYCXAOBSRM-JXMROGBWSA-N

InChi Code: InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10, 21H, 11-14H2, (H, 22, 23)/b10-7+

SMILES Code: O=C(C1=CC=C(/C=C/C2=NNC3=C2C=CC=C3)C=C1)N4CCNCC4